Therefore, targeting STAT3 by small molecule inhibitor FLLL32 could be a potential therapeutic strategy for inhibiting pancreatic cancer progression and overcoming chemo/radio-resistance. Here, STAT3 is linked to familial pancreatic carcinoma.